MENU
+Compare
ICCC
Stock ticker: NASDAQ
AS OF
Apr 25, 02:02 PM (EDT)
Price
$5.48
Change
-$0.02 (-0.36%)
Capitalization
49.4M

ICCC ImmuCell Corp Forecast, Technical & Fundamental Analysis

ImmuCell Corp is engaged in the healthcare sector... Show more

ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ICCC with price predictions
Apr 24, 2025

ICCC in upward trend: 10-day moving average moved above 50-day moving average on April 09, 2025

The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on April 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 09, 2025. You may want to consider a long position or call options on ICCC as a result. In of 120 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ICCC just turned positive on March 28, 2025. Looking at past instances where ICCC's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ICCC moved above its 50-day moving average on April 11, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 127 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ICCC broke above its upper Bollinger Band on April 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.795) is normal, around the industry mean (14.237). P/E Ratio (0.000) is within average values for comparable stocks, (63.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.827). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.695) is also within normal values, averaging (255.011).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of products for cattle health

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
56 Evergreen Drive
Phone
+1 207 878-2770
Employees
79
Web
https://www.immucell.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LPX87.032.47
+2.92%
Louisiana-Pacific Corp
CNDT2.140.06
+2.88%
Conduent
XPL0.630.02
+2.81%
Solitario Resources Corp
TDG1368.0216.02
+1.18%
TransDigm Group
GTY27.57-0.94
-3.30%
Getty Realty Corp

ICCC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
N/A
NKTX - ICCC
43%
Loosely correlated
+0.92%
ATHE - ICCC
27%
Poorly correlated
+0.85%
BOLT - ICCC
26%
Poorly correlated
+4.57%
IMMP - ICCC
23%
Poorly correlated
+3.70%
MYNDF - ICCC
23%
Poorly correlated
N/A
More